ADAMTS Proteinases: Potential Therapeutic Targets?

Title: ADAMTS Proteinases: Potential Therapeutic Targets?

Volume: 7 Issue: 1

Author(s): Gavin C. Jones

Affiliation:

Keywords: ADAMTS, metalloproteinase, regulation, therapy

Abstract: ADAMTS (a disintegrin and metalloproteinase with thrombospondin motifs) proteinases have been implicated in a number of connective tissue pathologies including Ehlers-Danlos syndrome type VII C, Weill-Marchesani syndrome, encephalomyelitis, and arthritis. These proteinases therefore represent potential therapeutic targets for the treatment of such conditions. The synthesis and activity of ADAMTS proteinases is regulated at multiple levels: transcription, RNA splicing, translation, proteolytic processing, cofactor stimulation and inhibition, each of which represents a possible point of therapeutic intervention. Recent research suggests that, in addition to the direct inhibition of ADAMTS proteinases with low molecular weight non-peptidic inhibitors, targeting the transcription and protein processing of these enzymes could be effective therapeutic approaches.

Cite this article as:

Jones C. Gavin, ADAMTS Proteinases: Potential Therapeutic Targets?, Current Pharmaceutical Biotechnology 2006; 7 (1) . https://dx.doi.org/10.2174/138920106775789656